Introduction
Over the past decade, 9-p-D-arabinofuranosyladenine (araA) and its highly water-soluble 5'-monophosphate derivative (araAMP) have been extensively studied and have shown some clinical benefits in the treatment of chronic hepatitis B virus (HBy) infection (Pollard et al., 1978; Bassendine et al., 1981; Weller et al., 1985) . Unfortunately, the clinical use of araA and araAMP is hampered by dose-dependent adverse effects. The major toxicities include a neuropathic pain syndrome (Hoofnagle et al., 1984) and muscular pains (Smith et al., 1982) , which limit drug evaluation at higher dosages and for extended treatment periods. In order to reduce these toxicities, liver targeting, using a carrier which is capable of delivering araAMP specifically to the hepatocytes, may lead to a more selective inhibition of HBV replication, as suggested by several groups. Indeed, previous studies have indicated that when araAMP is given as a conjugate with lactosaminated human serum albumin (L-HSA), a neoglycoprotein that specifically penetrates hepatocytes (Wilson, 1978; Fiume et al., 1986) , inhibition of HBV replication by this conjugate occurred at a third to a sixth of the unconjugated araAMP dose (Fiume et al., 1988) . However, immunogenicity and the formation of hepatic vacuoles associated with lactosylated albumin (Fiume et al., 1987; brought into questioned the safety of this protein carrier. Recently, arabinogalactan, a polysaccharide from the tree Larix occidenta/is, has been purified; subsequent metabolic and toxicological studies of this naturally occurring polysaccharide suggested that it may represent a suitable carrier for delivering diagnostic and therapeutic agents to hepatocytes via the asialoglycoprotein receptor (Groman et al., 1994) . AraAMP coupled to arabinogalactan (about 8 mol araAMP for each mol conjugate) exhibited a strong inhibition of woodchuck hepatitis virus (WHV) in a relevant woodchuck model after administration of a dose as low as 0.3 mg kg-1 day'". No toxicity was observed after administration of AG (9kDa)-araAMP, up to a dose of 3 mg kg-1 day-1 for 14 days (Josephson etal., 1996) .
In the wake of the tragic clinical trial with 1-(2-deoxy-2-fluoro-~-D-arabinofuranosyl)-5-iodouracil (FIAU), it has become widely recognized that any nucleoside analogue developed as a potential anti-hepatitis drug must be evaluated for its eventual effects on host mitochondria. Our previous investigation on the mechanisms involved in FIAU-induced liver toxicity has demonstrated that drug effects on HepG2 cells were consistent with the clinical observations, suggesting that the HepG2 cell line may be a relevant model for evaluating possible mitochondrial hepatotoxicity (Cui et al., 1995) . These studies were recently extended to various nucleoside analogues which are potential candidates for treatment of HBV infection and this in vitro model was further demonstrated to be a good prognosticator of delayed drug hepatotoxicity (Cui et al., 1996) . In the present paper, we examined the effects of AG (9kDa)-araAMP on HBV replication in 2.2.15 cells as well as its eventual effects on mitochondrial function in HepG2 cells. In order to evaluate the advantage of this conjugate, these results were compared with those obtained with the parent drug, araA, and its metabolite, araH.
Materials and Experimental Procedures
Reagents AraA, araH, araATP, araAMP, proteinase K and'Rl'[ase H were purchased from Sigma. AG (9kDa)-araAMP and carboxymethyl arabinogalactan (AG) were synthesized by 530 Advanced Magnetics according to previously published procedures (Josephson et al., 1996) . [3H]dATP (34 Ci mmol'"), [a-32 PJdCT P (3000 Ci mmol") and [a-32P]dATP (3000 Ci mmol'") were purchased from ICN. QyikHyb hybridization solution was purchased from Stratagene. Lactic acid assay kit was purchased from Boehringer Mannheim. MEM with non-essential amino acids, sodium pyruvate, dialysed fetal bovine serum and 10xtrypsin-EDTA were purchased from Gibco BRL. All others chemicals and reagents were of the highest analytical grade available.
Cell culture, drug treatment and anti-HBV assay
The HBV-transfected human hepatoblastoma-derived cell line HepG2 (2.2.15) was cultured as described by Korba & Guerin (1992) with minor modifications. Briefly, cells were cultured at a density of 2x10 5 cells mL-1 in 24-well plates, incubated with test drugs in Dulbecco's modified Eagle's medium supplemented with 4% fetal bovine serum and an additional 0.5 mM glutamine for 9 days. Medium with drugs was changed every 3 days. At harvest, total intracellular DNA was extracted and digested with HindIII, and subsequently analysed by Southern blot to evaluate the intracellular HBV DNA content, Filters were first dried and then hybridized with a [a-32 P]dCT Plabelled HBV-specific probe, using the plasmid pTHBV, which contains the full-length HBV genome. Prehybridization, hybridization and washes were performed according to the manufacturer's instructions when using QyikHyb hybridization solution. After exposure of the filters, the bands were quantified using a Shimadzu CS 9000 U flying-spot densitometer. The integrated HBV DNA, which remained constant, was used as an internal control to standardize the amounts of DNA loaded. For analysis of mtDNA content in 2.2.15 cells, the membrane was washed twice in boiled O.lxSSC plus 0.1% SDS for 15 min to remove the HBV probe and rehybridized with [a-32PJdATP-Iabelled specific human oligonucleotide mitochondrial probe (sp, act. 10 8-109 d.p.m, /-lg-l).
Effects of compounds on cell growth and lactic acid production
HepG2 cells were grown in 75 cm 2 tissue culture flasks in MEM with non-essential amino acids supplemented with 10% heat-inactivated dialysed fetal bovine serum, 1% sodium pyruvate and 1% penicillin/streptomycin. The medium was changed every 3 days and cells were subcultured once a week. For experiments, HepG2 cells were plated into 12-well cell culture clusters with 5x10 4 cells in 2 mL medium in each well. Various concentrations of drugs or no drug (control) were added to the medium of each well. After 4 days of incubation, the cells were removed from the bottom of each well using 0.05% trypsin-0.02% EDTA and counted with a haemocytometer under the microscope. Cell viability, as assessed by trypan blue exclusion, was 95% or greater during experiments. Meanwhile, the medium in each well was collected and filtered using Aero disc LC13 PVDF from Fisher Scientific (Pittsburgh, Pa., USA). The lactic acid content in the medium was measured using a lactic acid assay kit (Boehringer Mannheim), following the supplier's instructions. The amount of lactic acid in the medium was expressed as mg oflactic acid production per 10 6 cells.
Effects of compounds on mtDNA content
HepG2 cells (2.5x10 4 cells mL-l) were plated into 12-well cell culture clusters and treated with varying concentrations of compounds or no compound (control). After 4 days of incubation, fresh medium containing the test compound was added and changed every other day until termination of the experiment at 14 days. Cells were then collected, and 5x10 4 cells sample" were suspended in a 0.5 mL mixture of 0.4 M NaOH and 10 mM EDTA, and heated at 100·C for 10 min. The DNA in the supernatant was immobilized on a Zeta-Probe membrane (Bio-Rad) using a slot-blot apparatus. The blotted membrane was rinsed briefly in 2xSSC and dried at '80·C for 30 min. To detect the mtDNA on the membrane, the membrane was hybridized with [a-32 P]dAT P-Iabelled specific human oligonucleotide mitochondrial probe (108-10 9 d.p.m. !!g-l), encompassing nucleotide positions 4212-4242 (Anderson et al., 1981) . The hybridized membrane was exposed to X-ray film at -80·C for 4 days, using an intensifying screen. The membrane was then washed twice in boiled O.lxSSC plus 0.1% SDS for 15 min to remove the mtDNA probe. The amount of total cellular DNA loaded on the membrane was standardized by a gel-purified 625 bp fragment of a human~-actin cDNA plasmid, labelled with [a-32 P]dCT P. Finally, the autoradiograms were scanned using a Shimadzu CS 9000U flying-spot densitometer.
Electron microscope evaluation
HepG2 cells (2.5x10 4 cells mL-l) were plated into 35x10 mm tissue culture dishes and selected concentrations of compound or no compound (control) were added to each dish. After a 4 day incubation period, medium with and without (control) compounds was added and changed every other day. At day 8, cellswere fixed in 1%glutaraldehyde for 1 h, rinsed in sodium phosphate buffer, and postfixed in 1% osmium tetroxide for 1 h. The cells were then gradually dehydrated with graded concentrations of ethanol starting with 50% through 100% to propylene oxide and subsequently infiltrated and embedded in epon. Lastly, cells were sectioned with a Reichert-jung ultramicrotome, stained with uranyl acetate and lead citrate, and examined with a Hitachi 7000 electron microscope. 
Results
In vitro anti-HBVactivities of araA, araH, and AG (9kDa)-araAMP as assessed in 2.2.15 cells; effects of araATP on WHV DNA polymerase
The anti-HBV activity of AG (9kDa)-araAMP was 25fold more potent than that of araA, as measured by their respective EC so values based on the intracellular replicative intermediate HBV DNA levels in 2.2.15 cells. In contrast, araH had no effect up to 100 !!M on HBV replication in 2.2.15 cells (Table 1) . 3TC, a positive control in this assay, exhibited an EC so of 0.05 !!M. Furthermore, AG (9kDa)-araAMP was not substantially toxic to HepG2 cell growth up to a concentration of 822 !!M, demonstrating its in vitro selective anti-HBV effect. In contrast, araA inhibited HepG2 cell proliferation with an IC so of 46 !!M, resulting in a poor selectivity index. AG (9kDa)-araAMP had no effect on mtDNA synthesis in 2.2.15 cells at any studied concentrations between 0.1 !!M and 50 !!M. An in vitro enzymatic assay demonstrated that araATP inhibited WHV DNA polymerase with an rc., of 5 !!M.
Effects of compounds on HepG2 cell growth and lactic acid production
To assessthe effects of studied compounds on HepG2 cell growth and lactic acid production, cells were exposed to selected concentrations of compounds for 4 days.
Treatment of cells with 10 !!M of 3TC and 10 I!M of FIAU was used as a negative and a positive control, respectively. Table 2 shows that 822 !!M [all concentra- 
Morphological examination
HepG2 cellsincubated for 7 days with studied compounds at selected concentrations were evaluated by electron microscopy. Electron micrographs revealed that large amounts oflipid droplets were formed in cells treated with 10~ofFIAU, as previouslypublished (Cui etal., 1995) .
In addition, some mitochondria in the cells were enlarged and lost their cristae, whereas others were still intact in shape and structure. No difference compared to the control was noted in cells incubated with 10 I-lM 3TC. Meanwhile, no mitochondrial alteration or increased cytoplasmic lipid droplet formation was detected in cells exposed to either 82.2 !!M or 822 I-lM ( Fig. 1 ) AG (9kDa)-araAMP, or to either 8.22 !!M or 82.2 !!M of araA. In contrast, a slight loss of cristae was observed in cells treated with araH at 8.22 I-lM and 82.2 !!M (Fig. 2 ).
Discussion
In order to improve the therapeutic efficacy of nucleoside analogues and eliminate their possible extrahepatic side effects, several liver targeting carriers, including recombinant chylomicrons (Rensen et aI., 1995) , L-HSA (Fiume et al., 1986) and more recently arabinogalactan (Groman et al., 1994) , have been developed in order to deliver specifically the antiviral agent to the hepatocytes, the main site of HBV infection and replication.
In the present study,AG (9kDa)-araAMP was 25 times more active than araA itself, as measured by the HBV DNA intracellular replicative intermediate levels in 2.2.15 cells, indicating that AG (9kDa)-araAMP is a potent and selective agent against HBV replication in vitro. Both araA and its derivatives are believed to exert their anti-HBV effects by inhibiting HBV DNA polymerase through araATP. Hess et al. (1981) had previously reported an inhibition of Dane particle-associated DNA polymerase by araATP with an IC so of approximately 1 !!M, a value in the same range as that obtained in the present study with WHV DNA polymerase (EC so 5 I-lM). The antiviral activity of AG (9kDa)-araAMP was not influenced by the presence of 5-iodotubercidin, an inhibitor of adenosine kinase, suggesting that this conjugate released the phosphorylated form of araA into the cells (Josephson et al., 1996) . Therefore, the more potent in vitro activity of AG (9kDa)-araAMP as compared to araA against HBV replication is probably due to the enhanced araATP levels formed inside the cells subsequent to the efficient arabinogalactan transport of araAMP via the asialoglycoprotein receptors present on the cells. Because araAMP is converted to its 5'-triphosphate through a direct pyrophosphate transfer from 5phosphoribosyl-1-pyrophosphate (PRPP) by PRPP synthetase, with only about 5% efficiencywhen compared to AMP phosphorylation (Balzarini & De Clercq, 1990 ), a high intracellular concentration of araAMP is definitely necessary for its efficient phosphorylation to araATP. Furthermore, release of araAMP by AG (9kDa)-araAMP into cells also possibly avoids the rapid deamination of araA to its inactive metabolite araH (Agarwal et aI., 1975) , which is potentially an additional limiting factor in the chemotherapeutic effectiveness of araA. 534 Recent reports have indicated that delayed mitochondrial toxicity may be partly responsible for nucleosiderelated adverse effects (Parker & Cheng, 1994; Swartz, 1995) and our group.has demonstrated that marked mitochondrial dysfunction was a major mechanism involved in FIAU-induced liver toxicity (Cui et al., 1995) . In the current study, both araA and araH induced a dose-dependent increase in lactic acid production in HepG2 cells, reflecting an impairment of mitochondrial morphology and function (Table 2, Fig. 2 ). On the other hand, AG (9kDa)-araAMP had no effect on either lactic acid production or cell growth at the same araA equivalent concentrations. Only a minor effect was detected in both assays when cellswere exposed to AG (9kDa)-araAMP at an araA equivalent concentration 10-fold greater than the highest concentration tested with araA or araH, implying that only high concentrations of AG (9kDa)-araAMP affect nuclear DNA synthesis. As for mtDNA synthesis, exposure to AG (9kDa)-araAMP under the concentrations studied caused no effect as compared to the control, whereas both araA and araH treatment led to a dosedependent reduction in mtDNA content (Table 2) . It is important to note that despite the reported clinical neuropathy and myopathy observed in clinical trials after administration of araA or araAMP, the underlying mechanism(s) ofthese toxicities have not been clearly explained. In contrast to the previously proposed mechanism for ddC-and ddI-related peripheral neuropathy (Chen & Cheng, 1989; Chen et al., 1991) , inhibition of human DNA polymerase y by araATP was rather weak and probably accounted only partially for the observed inhibition of mtDNA synthesis. Several studies have reported that araAMP is incorporated into cellular and viral DNA via internucleotide linkages, since araAMP, in contrast to 2',3'-dideoxynucleosides, contains a 3'-hydroxyl group (Plunkett & Cohen, 1975; Pelling et al., 1979; Derse & Cheng, 1981) . More recent studies indicated that DNA polymerase a-associated DNA primase, which is responsible for RNA primer formation, appears to be the main target for inhibition by araATP, and the effect of araATP on subsequent chain elongation is highly dependent on the primer/template used in the assays (Kuchta et al., 1992; Thompson & Kuchta, 1995) . Although DNA polymerase y has been identified to be the essential enzyme for mtDNA replication, much less is known about mtDNA synthesis than its nuclear counterpart. In contrast to nuclear DNA replication, endonuclease G was found to generate primers for mtDNA replication (Cote & Ruiz-Carrillo, 1993) . Based on the present study, impairment of mitochondrial functions by araA is probably the result of the incorporation of araAMP into the mitochondrial genome. The reduction of mtDNA content (Table 2) may possibly reflect inefficient DNA chain elongation following sites of araAMP incorporation. AraH is usually considered to be a non-pharmacologically important metabolite of araA, being at least 10-to 50-fold less inhibitory than the parent drug against the replication of DNA viruses (Shipman et al., 1981) . Unlike its antiviral activity, based on the data herein, araH is very probably a toxic metabolite in vivo, which further exarcerbates the toxicity of the parent drug by inducing mitochondrial dysfunction. This is evident from its inhibition of mtDNA synthesis, combined with morphological changes of mitochondria, with loss of cristae and matrix dissolution (Fig.  2) . The toxic effects of araH are also probably dependent on its 5'-triphosphate derivative, following phosphorylation within mitochondria and/or cellular phosphorylation followed by nucleotide transport to the mitochondria.
Elucidation of the mechanism(s) underlying the increased selectivity of AG (9kDa)-araAMP as compared to araA would require a more detailed understanding of the cellular pharmacology of AG (9kDa)-araAMP. In addition to our earlier discussion on their anti-HBV activity, we postulate that the intracellular disposition of araAMP liberated by the conjugate is likely to be different from that of the mononucleotide formed by phosphorylation after uptake of araA. Furthermore, the conjugate, by liberating araAMP intracellularly, may bypass the transport of araA through the mitochondrial membrane, resulting ultimately in an inefficient accumulation of araATP within the mitochondria. The reduced cytotoxicity with AG (9kDa)-araAMP may also be due to the absence of intracellular araA. As demonstrated in previous studies, araA itself inhibits S-adenosyl-L-homocysteine hydrolase, resulting in an accumulation of S-adenosyl-L-homocysteine, which is a feedback inhibitor of S-adenosylmethionine-dependent transmethylases (Hershfield, 1979; Zimmerman et al, 1980; Helland & Ueland, 1982) . The decreased methylation of macromolecules including DNA, RNA and protein as a result of this inhibitory effect on transmethylases has been suggested to be a major mechanism of host cell cytotoxicity (Cass et al., 1982) and, therefore, the lack of intracellular araA when using the conjugate may have a profound effect on the ultimate selectivity.
In summary, our present study demonstrates that AG (9kDa)-araAMP is substantially more potent against HBV replication than araA in vitro and, most importantly, its selectivity as compared to araA toward mitochondria is markedly increased. The data are supportive of further development of this novel a~ti-HBV candidate.
